Hit By Earthquake and U.S. Restructuring, Shionogi Looks To Regroup In Time For Crestor Loss
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi & Co. Ltd. is fighting a two-front battle, recovery from the March 2011 earthquake and tsunami in Northern Japan and restructuring of its U.S. acquisition. The company formulated a mid-term plan to address ways to buffer the September 2016 patent loss of Crestor (rosuvastatin), by far the company's most important drug, but setbacks in the U.S. raise doubts about the company's ability to counter the patent cliff
You may also be interested in...
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.
Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.